AG˹ٷ

STOCK TITAN

[6-K] Oculis Holding AG Ordinary shares Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) � Form 144 notice

An unidentified affiliate has filed to sell up to 6,053 ordinary shares via Citigroup Global Markets on the NYSE, with an aggregate market value of roughly US$91,748. The shares were acquired as a restricted-share-unit award on 01 Aug 2022 and satisfy Rule 144’s two-year holding-period requirement. The proposed trade window opens on 01 Aug 2025.

Teva has about 1.147 billion shares outstanding, so the sale would equal <0.001 % of the float—far below any level that could affect liquidity, ownership concentration or voting control. A Form 144 is only a notice; the transaction may not ultimately occur and no pricing details were provided beyond the broker of record.

Teva Pharmaceutical Industries Ltd. (TEVA) � Avviso Modulo 144

Un affiliato non identificato ha presentato una comunicazione per vendere fino a 6.053 azioni ordinarie tramite Citigroup Global Markets alla NYSE, con un valore di mercato complessivo di circa 91.748 USD. Le azioni sono state acquisite come premio in unità azionarie vincolate il 1° agosto 2022 e soddisfano il requisito del periodo di detenzione di due anni previsto dalla Regola 144. La finestra di negoziazione proposta si apre il 1° agosto 2025.

Teva ha circa 1,147 miliardi di azioni in circolazione, quindi la vendita corrisponderebbe a meno dello 0,001% del flottante—molto al di sotto di qualsiasi livello che potrebbe influire sulla liquidità, concentrazione della proprietà o controllo di voto. Il Modulo 144 è solo un avviso; la transazione potrebbe non avvenire e non sono stati forniti dettagli sui prezzi oltre al broker di riferimento.

Teva Pharmaceutical Industries Ltd. (TEVA) � Aviso Formulario 144

Un afiliado no identificado ha presentado para vender hasta 6,053 acciones ordinarias a través de Citigroup Global Markets en la NYSE, con un valor de mercado agregado de aproximadamente 91,748 USD. Las acciones fueron adquiridas como premio de unidades restringidas el 1 de agosto de 2022 y cumplen con el requisito de período de retención de dos años de la Regla 144. La ventana de negociación propuesta se abre el 1 de agosto de 2025.

Teva tiene aproximadamente 1.147 mil millones de acciones en circulación, por lo que la venta equivaldría a menos del 0.001% del flotante—muy por debajo de cualquier nivel que pueda afectar la liquidez, concentración de propiedad o control de voto. Un Formulario 144 es solo un aviso; la transacción puede no ocurrir finalmente y no se proporcionaron detalles de precios más allá del corredor registrado.

테바 제약 산업 주식회사(TEVA) � Form 144 통지

신원 미상� 계열사가 Citigroup Global Markets� 통해 NYSE에서 6,053 보통�까지 매도 신청� 했으�, � 시장 가치는 � 91,748 미국 달러입니�. 해당 주식은 2022� 8� 1� 제한 주식 단위 보상으로 취득되었으며, Rule 144� 2� 보유 요건� 충족합니�. 제안� 거래 창은 2025� 8� 1�� 열립니다.

테바� � 11� 4,700� �� 주식� 발행했으�, 이번 매도� 유동 주식� 0.001% 미만� 해당하여 유동�, 소유 집중� 또는 의결권에 영향� 미칠 수준보다 훨씬 낮습니다. Form 144� 단지 통지� 뿐이�, 거래가 실제� 이루어지지 않을 수도 있고, 중개� 외에 가� 정보� 제공되지 않았습니�.

Teva Pharmaceutical Industries Ltd. (TEVA) � Avis de Formulaire 144

Un affilié non identifié a déposé une demande pour vendre jusqu'à 6 053 actions ordinaires via Citigroup Global Markets à la NYSE, avec une valeur marchande totale d'environ 91 748 USD. Les actions ont été acquises en tant qu'attribution d'unités d'actions restreintes le 1er août 2022 et remplissent l'exigence de détention de deux ans selon la règle 144. La fenêtre de négociation proposée s'ouvre le 1er août 2025.

Teva compte environ 1,147 milliard d'actions en circulation, de sorte que la vente représenterait moins de 0,001 % du flottant � bien en dessous de tout niveau pouvant affecter la liquidité, la concentration de la propriété ou le contrôle des votes. Un formulaire 144 est uniquement un avis ; la transaction pourrait ne pas avoir lieu et aucun détail sur les prix n'a été fourni en dehors du courtier enregistré.

Teva Pharmaceutical Industries Ltd. (TEVA) � Form 144 Mitteilung

Ein nicht identifizierter Beteiligter hat den Verkauf von bis zu 6.053 Stammaktien über Citigroup Global Markets an der NYSE gemeldet, mit einem gesamtmarktwert von etwa 91.748 US-Dollar. Die Aktien wurden am 1. August 2022 als Restricted-Share-Unit-Auszeichnung erworben und erfüllen die zweijährige Haltefrist gemäß Regel 144. Das vorgeschlagene Handelsfenster öffnet am 1. August 2025.

Teva hat etwa 1,147 Milliarden Aktien ausstehend, sodass der Verkauf weniger als 0,001 % des Streubesitzes ausmachen würde � weit unter jedem Niveau, das Liquidität, Eigentumskonzentration oder Stimmrechtskontrolle beeinflussen könnte. Ein Form 144 ist lediglich eine Mitteilung; die Transaktion könnte letztlich nicht stattfinden und es wurden keine Preisangaben außer dem zuständigen Broker gemacht.

Positive
  • None.
Negative
  • Insider selling signal: Even though the volume is trivial, any planned insider sale can be perceived negatively by some investors tracking management sentiment.

Insights

TL;DR: De minimis insider sale; neutral for valuation.

The 6,053-share sale equates to under US$0.1 m against Teva’s multi-billion-dollar market cap and >1 billion share count. Such a small disposition will not affect liquidity or EPS and does not imply strategic change. Insider intent might garner minor attention, but the transaction volume is immaterial. Overall, I view the filing as routine administrative disclosure with no discernible impact on the investment thesis.

TL;DR: Routine Rule 144 compliance; governance risk unchanged.

The filer certifies no undisclosed adverse information, satisfying Rule 144 and 10b5-1 safeguards. Absence of recent clustered insider selling or large volume keeps governance risk unchanged. I classify the event as not impactful to shareholders� governance considerations.

Teva Pharmaceutical Industries Ltd. (TEVA) � Avviso Modulo 144

Un affiliato non identificato ha presentato una comunicazione per vendere fino a 6.053 azioni ordinarie tramite Citigroup Global Markets alla NYSE, con un valore di mercato complessivo di circa 91.748 USD. Le azioni sono state acquisite come premio in unità azionarie vincolate il 1° agosto 2022 e soddisfano il requisito del periodo di detenzione di due anni previsto dalla Regola 144. La finestra di negoziazione proposta si apre il 1° agosto 2025.

Teva ha circa 1,147 miliardi di azioni in circolazione, quindi la vendita corrisponderebbe a meno dello 0,001% del flottante—molto al di sotto di qualsiasi livello che potrebbe influire sulla liquidità, concentrazione della proprietà o controllo di voto. Il Modulo 144 è solo un avviso; la transazione potrebbe non avvenire e non sono stati forniti dettagli sui prezzi oltre al broker di riferimento.

Teva Pharmaceutical Industries Ltd. (TEVA) � Aviso Formulario 144

Un afiliado no identificado ha presentado para vender hasta 6,053 acciones ordinarias a través de Citigroup Global Markets en la NYSE, con un valor de mercado agregado de aproximadamente 91,748 USD. Las acciones fueron adquiridas como premio de unidades restringidas el 1 de agosto de 2022 y cumplen con el requisito de período de retención de dos años de la Regla 144. La ventana de negociación propuesta se abre el 1 de agosto de 2025.

Teva tiene aproximadamente 1.147 mil millones de acciones en circulación, por lo que la venta equivaldría a menos del 0.001% del flotante—muy por debajo de cualquier nivel que pueda afectar la liquidez, concentración de propiedad o control de voto. Un Formulario 144 es solo un aviso; la transacción puede no ocurrir finalmente y no se proporcionaron detalles de precios más allá del corredor registrado.

테바 제약 산업 주식회사(TEVA) � Form 144 통지

신원 미상� 계열사가 Citigroup Global Markets� 통해 NYSE에서 6,053 보통�까지 매도 신청� 했으�, � 시장 가치는 � 91,748 미국 달러입니�. 해당 주식은 2022� 8� 1� 제한 주식 단위 보상으로 취득되었으며, Rule 144� 2� 보유 요건� 충족합니�. 제안� 거래 창은 2025� 8� 1�� 열립니다.

테바� � 11� 4,700� �� 주식� 발행했으�, 이번 매도� 유동 주식� 0.001% 미만� 해당하여 유동�, 소유 집중� 또는 의결권에 영향� 미칠 수준보다 훨씬 낮습니다. Form 144� 단지 통지� 뿐이�, 거래가 실제� 이루어지지 않을 수도 있고, 중개� 외에 가� 정보� 제공되지 않았습니�.

Teva Pharmaceutical Industries Ltd. (TEVA) � Avis de Formulaire 144

Un affilié non identifié a déposé une demande pour vendre jusqu'à 6 053 actions ordinaires via Citigroup Global Markets à la NYSE, avec une valeur marchande totale d'environ 91 748 USD. Les actions ont été acquises en tant qu'attribution d'unités d'actions restreintes le 1er août 2022 et remplissent l'exigence de détention de deux ans selon la règle 144. La fenêtre de négociation proposée s'ouvre le 1er août 2025.

Teva compte environ 1,147 milliard d'actions en circulation, de sorte que la vente représenterait moins de 0,001 % du flottant � bien en dessous de tout niveau pouvant affecter la liquidité, la concentration de la propriété ou le contrôle des votes. Un formulaire 144 est uniquement un avis ; la transaction pourrait ne pas avoir lieu et aucun détail sur les prix n'a été fourni en dehors du courtier enregistré.

Teva Pharmaceutical Industries Ltd. (TEVA) � Form 144 Mitteilung

Ein nicht identifizierter Beteiligter hat den Verkauf von bis zu 6.053 Stammaktien über Citigroup Global Markets an der NYSE gemeldet, mit einem gesamtmarktwert von etwa 91.748 US-Dollar. Die Aktien wurden am 1. August 2022 als Restricted-Share-Unit-Auszeichnung erworben und erfüllen die zweijährige Haltefrist gemäß Regel 144. Das vorgeschlagene Handelsfenster öffnet am 1. August 2025.

Teva hat etwa 1,147 Milliarden Aktien ausstehend, sodass der Verkauf weniger als 0,001 % des Streubesitzes ausmachen würde � weit unter jedem Niveau, das Liquidität, Eigentumskonzentration oder Stimmrechtskontrolle beeinflussen könnte. Ein Form 144 ist lediglich eine Mitteilung; die Transaktion könnte letztlich nicht stattfinden und es wurden keine Preisangaben außer dem zuständigen Broker gemacht.

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2025

(Commission File No. 001-41636)

 

 

Oculis Holding AG

(Translation of registrant’s name into English)

 

 

Bahnhofstrasse 20

CH-6300

Zug, Switzerland

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

 

 
 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Amended Loan Facility

On July 31, 2025, Oculis Holding AG (the “Registrant”) entered into an amended and restated agreement for its existing loan facility (the “Amended Loan Agreement”) with Kreos Capital VII (UK) Limited (the “Lender”), which are funds and accounts managed by BlackRock, Inc. No amount was drawn at the signing of the Amended Loan Agreement. The Amended Loan Agreement replaces the prior loan agreement between the Registrant and the Lender dated May 29, 2024, with an upsized structure to provide the EUR equivalent of up to CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the “Loan”), comprising tranches 1, 2 and 3, in the amounts of the EUR equivalents of CHF 25.0 million each, as well as an additional loan of the EUR equivalent of up to CHF 25.0 million, which may be made available by the Lender to the Registrant if mutually agreed in writing by the Lender and the Registrant.

Loan 1 will be available for drawdown from closing until November 15, 2026, which period may be shortened upon the occurrence of a development milestone. Loans 2 and 3 will be available for drawdown prior to November 15, 2026 and December 31, 2026, respectively, in each case subject to satisfaction of certain pre-specified conditions. The availability of any funds under a drawdown of Loans 1, Loan 2 or Loan 3 is conditional upon, together with other conditions, the Registrant having a debt-to-market cap ratio (where debt includes the amount of all amounts drawn down to date and the proposed drawdown) equal to or less than 15% at the time of each draw down.

Borrowings under Loan 1, 2 and 3 will bear interest at a fixed rate (cash and PIK) of 9.7%, 9.6% and 9.5% per annum, respectively. The Loan will have an interest-only period of, in respect of Loans 1, 2 and 3, from the relevant drawdown date until December 31, 2027, March 31, 2028 and June 30, 2028, respectively. The interest-only periods for each of Loans 1 and 2 will be shortened to December 31, 2026 if certain conditions are not met. In the event the interest-only periods for Loans 1 and 2 are shortened, Loans 1 and 2 will mature on 30 June 2029. In the event the interest-only periods are not shortened, Loans 1, 2 and 3 will expire on 31 December 2029.

The Registrant may prepay all, but not part, of the term loan amounts at any time other than, unless the Lender agrees otherwise, by notifying the Lender in advance. The Loan is subject to mandatory prepayment in the event of a change of control or specified asset dispositions or licenses, subject to certain exceptions and thresholds. There are additional fees (including prepayment premia) payable to the Lender in the event the loan is prepaid either mandatorily or voluntarily. The Lender received a restatement fee of approximately CHF 500,000 in connection with the Amended Loan Agreement. The Lender is eligible to receive an aggregate of approximately CHF 562,500 in additional transaction fees payable upon the Registrant’s eligibility to receive and actual receipt of future drawdowns. The Lender will be eligible to receive certain non-utilisation fees. On the date on which the Loan is prepaid or falls due for repayment in full, the Lender is eligible to receive an end of loan fee of, in relation to each of Loans 1, 2 and 3, 4.5% of the amount drawn down under the relevant loan. The Loan contains customary affirmative and negative covenants.

As additional consideration for the Loan, Kreos Capital VII Aggregator SCSp, an affiliate of the Lender (the “Holder”), and the Registrant entered into an amended warrant (the “Amended Warrant”) to purchase up to 494,259 of the Registrant’s ordinary shares, subject to vesting, at a price per ordinary share equal to $12.17 with respect to 361,011 shares from the prior warrant agreement, and $18.64 with respect to the remaining 133,248 shares reflecting the upsized facility, subject to adjustment (the “Exercise Price”). The Amended Warrant amends the prior warrant issued to Holder on May 29, 2024. As of the signing date, the Amended Warrant is exercisable for 59,310 ordinary shares, of which 43,321 shares were previously granted. Following the drawdown of each of Loans 1, 2 and 3, the Amended Warrant will become exercisable for additional amounts of ordinary shares ratably based on the amounts of Loans 1, 2 and 3 that are drawn. Each tranche of the Amended Warrant will be exercisable for a period of up to seven years from the date of vesting and the Amended Warrant will terminate at the earliest of (i) December 31, 2033, (ii) such earlier date on which the Amended Warrant is no longer exercisable for any warrant shares in accordance with its terms and (iii) the acceptance by the Registrant’s shareholders of a third-party bona fide offer for all outstanding shares of the Registrant (subject to any prior exercise by the Holder, if applicable). The Amended Warrant also includes customary F-3 resale and piggyback registration rights and anti-dilution provisions.


The Registrant intends to use the proceeds from the Amended Loan Agreement for general corporate purposes.

The foregoing summaries of the Amended Loan Agreement and the Amended Warrant are not complete and are qualified in their entirety by reference to the full text of the Amended Loan Agreement and the Amended Warrant, respectively, copies of which the Registrant expects to file no later than with its Annual Report on Form 20-F for the fiscal year ending December 31, 2025.

INCORPORATION BY REFERENCE

This information contained in this Report on Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File Nos. 333-271938 and 333-287806) and Form F-3 (File Nos. 333-281798, 333-278409 and 333-271063).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    OCULIS HOLDING AG
Date: August 1, 2025     By:  

/s/ Sylvia Cheung

     

Sylvia Cheung

Chief Financial Officer

FAQ

What did the TEVA Form 144 disclose?

It disclosed an insider's intent to sell 6,053 ordinary shares valued at about US$91,748.

When can the TEVA shares be sold under Rule 144?

The filing lists an approximate sale date of 01 Aug 2025.

How significant is the planned sale relative to TEVA’s float?

With 1.147 billion shares outstanding, the sale equals <0.001 % of total shares.

Where will the sale take place and who is the broker?

The shares are slated for sale on the NYSE through Citigroup Global Markets.

Were the shares purchased or awarded?

They were acquired as a restricted share-unit award on 01 Aug 2022.

Does the filing guarantee the transaction will occur?

No. Form 144 is only a notice; the insider may decide not to execute the sale.
Oculis Holding

NASDAQ:OCS

OCS Rankings

OCS Latest News

OCS Stock Data

904.83M
48.76M
7.04%
31.04%
0.05%
Biotechnology
Healthcare
Switzerland
Zug